Premenstrual Dysphoric Disorder and Antiepileptic Drugs

This study is being done to determine if there are differences in mood during the menstrual cycle among women with epilepsy who take various different antiepileptic drugs and women without epilepsy...

Date First Received: January 29, 2008

Last Updated: January 29, 2008

Verified by: Beth Israel Deaconess Medical Center, January 2008

Clinical Trial Phase: N/A | Start Date: November 2007

Overall Status: Recruiting

Estimated Enrollment: 100

Brief Summary

Official Title: “Comparison of Different Antiepileptic Drug Monotherapies for the Occurrence of Premenstrual Dysphoric Disorder Among Women With Epilepsy”

Condition Keyword(s):

This study is being done to determine if there are differences in mood during the menstrual cycle among women with epilepsy who take various different antiepileptic drugs and women without epilepsy.

Study Type: Observational

Study Design: Cohort, Prospective

Study Primary Completion Date: February 2009

Detailed Clinical Trial Description

Participants will be given informed consent during the initial study visit. We will gather information about their seizure disorder and medications and provide them with instructions and a form that they will complete daily for two months (two menstrual cycles). During the third week of each menstrual cycle, they will be asked to return once to provide a blood sample.

Arms, Groups and Cohorts in this Clinical Trial

  • : 1
    • Lamotrigine Monotherapy
  • : 2
    • Levetiracetam Monotherapy
  • : 3
    • Carbamazepine Monotherapy
  • : 4
    • Phenytoin Monotherapy
  • : 5
    • Normal control (no epilepsy)

Outcome Measures for this Clinical Trial

Primary Measures

  • To determine if the frequency of premenstrual dysphoric disorder differs among antiepileptic drug monotherapies.
    • Time Frame: 1 Year
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Women with epilepsy, 18-45 years of age. Women will be on one of 4 established (≥ 3 months) AED monotherapies: LTG, CBZ, PHT or LEV and with documented therapeutic range serum AED level during the year prior to enrollment.
  • Normal Control women, 18-45 years of age, in good general health by history

Exclusion Criteria:

  • Concomitant use of prescribed or OTC reproductive hormones
  • Concomitant use of antidepressant and anxiolytic medications such as SSRIs, bupropion, tricyclics, benzodiazepines

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 45 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Clinical Trial Sponsor Information

Lead Sponsor: Beth Israel Deaconess Medical Center

Overall Clinical Trial Officials and Contacts

Andrew G Herzog, MD Principal Investigator Beth Israel Deaconess Medical Center  

Overall Contact: Andrew G Herzog, MD 617 667 4523 

Additional Information

Information obtained from ClinicalTrials.gov on September 05, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00612235

Study ID Number: 2007-P-000357/2

ClinicalTrials.gov Identifier: NCT00612235

Health Authority: United States: Institutional Review Board

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.